A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Iovance Biotherapeutics Study Team
- Phone Number: 1-844-845-4682
- Email: Clinical.Inquiries@iovance.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90025
- Recruiting
- The Angeles Clinic and Research Institute
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Sylvester Comprehensive Cancer Center
-
Orlando, Florida, United States, 32610
- Recruiting
- Orlando Health Cancer Institute
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- Recruiting
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- University of Louisville
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10022
- Recruiting
- Weill Medical College of Cornell University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Recruiting
- UPMC Hillman Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Withdrawn
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC.
Participants who have received the following previous therapy:
- Cohort 1 (Melanoma): Participants who have progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhibitor in those with BRAF mutations.
Cohort 2 (NSCLC): Participants who should have received no more than 3 prior lines of therapy and:
- those without oncogene-driven tumors: Have progressed within 12 weeks after last dose of anti-PD-1/PD-L1 blocking antibody
those with oncogene-driven tumors: Have progressed during/after ≥1 targeted therapy AND either:
- platinum doublet chemotherapy
- Or within 12 weeks after last dose of anti-PD-1/PD-L1 blocking antibody
- Participants who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants who is assessed as having at least one resectable lesion.
- Participants who have at least one measurable lesion, following resection of the lesion for IOV-4001 generation.
- Participants who have adequate organ function.
- Cardiac function test required.
- Pulmonary function test may be required.
- Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months.
- Participants who are >70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
Exclusion Criteria:
- Participants who have melanoma of uveal/ocular origin.
- Participants who have symptomatic untreated brain metastases.
- Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.
- Participants who require systemic steroid therapy 10 mg/day prednisone or another steroid equivalent dose.
- Participants who have any form of primary immunodeficiency.
- Participants who have another primary malignancy within the previous 3 years.
- Participants who have received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMA-LD.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1
Participants with unresectable or metastatic melanoma
|
A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001.
After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
|
|
Experimental: Cohort 2
Participants with Stage III or IV non-small-cell lung cancer
|
A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001.
After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase I: Safety of IOV-4001
Time Frame: Up to 1 Year or depending on when the recommended phase 2 dose is determined
|
The safety of IOV-4001 will be assessed based on the totality of dose-limiting toxicity (DLT) and adverse event (AE) data collected during this phase
|
Up to 1 Year or depending on when the recommended phase 2 dose is determined
|
|
Phase 2: Objective Response Rate (ORR)
Time Frame: Up to 60 months
|
To evaluate the proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by the investigator
|
Up to 60 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CR Rate
Time Frame: Up to 60 months
|
To evaluate the proportion of participants who have a confirmed CR per RECIST v1.1 as assessed by the investigator
|
Up to 60 months
|
|
Duration of Response (DOR)
Time Frame: Up to 60 months
|
To evaluate the duration from the time that criteria are met for CR or PR per RECIST v1.1 as assessed by the investigator until disease progression or death due to any cause
|
Up to 60 months
|
|
Disease Control Rate (DCR)
Time Frame: Up to 60 months
|
To evaluate the percentage of participants with a best overall confirmed response of CR or PR at any time plus stable disease (SD) per RECIST v1.1 as assessed by the investigator
|
Up to 60 months
|
|
Progression-free Survival (PFS)
Time Frame: Up to 60 months
|
To evaluate the time from the date of IOV-4001 infusion until disease progression per RECIST v1.1 as assessed by the investigator or death due to any cause
|
Up to 60 months
|
|
Overall Survival (OS)
Time Frame: Up to 60 months
|
To evaluate the time from the date of IOV-4001 infusion to death due to any cause.
|
Up to 60 months
|
|
Feasibility of IOV-4001
Time Frame: Up to 60 months
|
This will be assessed by the proportion of participants who had tumor harvested and were treated without manufacturing delay or failure.
|
Up to 60 months
|
|
Safety and Tolerability of IOV-4001
Time Frame: Up to 60 months
|
This will be characterized by the severity, seriousness, relationship to study treatment, and characteristics of treatment-emergent adverse events (TEAEs).
|
Up to 60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Iovance Biotherapeutics Study Team, Iovance Biotherapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
- Cell Therapy
- NSCLC
- Carcinoma
- Non Small Cell Lung Cancer
- Melanoma
- Malignant melanoma
- Skin cancer
- PD-L1
- Systemic Therapy
- Tumor Infiltrating Lymphocytes
- IL-2
- Lung Disease
- TIL
- Bronchial Neoplasms
- Autologous Adoptive Cell Transfer
- Autologous Adoptive Cell Therapy
- Cellular Immuno-therapy
- Lifileucel
- Metastatic Melanoma
- Unresectable Melanoma
- Stage IV Melanoma
- CPI
- Stage III Melanoma
- Metastatic NSCLC
- Check point inhibitor
- Metastatic Non Small Cell Lung Cancer
- PD-1 Knockout
- Metastatic Lung Cancer
- Stage IV NSCLC
- Second line therapy
- Lung Carcinoma
- Stage III Non-small-cell lung cancer
- Stage IV Non-small-cell lung cancer
- Second line Lung Cancer
- Stage IV Cancer
- Stage IV Lung Cancer
- 2nd line therapy
- NSCLC Recurrent
- Recurrent Lung Cancer
- Recurrent Lung Carcinoma
- Skin cancer types
Additional Relevant MeSH Terms
- Neoplasms by Site
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Bronchial Diseases
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Skin Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Carcinoma, Bronchogenic
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin and Connective Tissue Diseases
- Neoplasms
- Lung Diseases
- Carcinoma
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Melanoma
- Skin Neoplasms
- Bronchial Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- IOV-GM1-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.